Over 80 known
autoimmune diseases.

Suboptimal treatments.

No cures.

We are bringing curative living medicines to life to free patients from the siege of autoimmune disease.

Our Opportunity

Navigating what’s next in synthetic biology, immunology and cell engineering to create a new class of T cell therapies programmed to target and selectively modulate the underlying causes of autoimmunity.

Our Story

Trailblazing Science Meets Unmet Patient Need

Kyverna is innovating cell therapy as a potentially curative approach to autoimmunity. Unlike current immunomodulatory treatments known to provide incremental disease control through chronic dosing, cell therapy holds the promise of modulating the immune system through a single – or relatively few – infusion(s) to achieve optimal and long-lasting disease control.

Trailblazing Science Meets Unmet Patient Need

Our Technology

Smart Science, Smarter Medicines

Kyverna is developing living therapies with multiple immunosuppressive mechanisms to help restore balance to the immune system. Our SmarTcellTM platform leverages advanced T cell engineering to target the underpinnings of autoimmunity: chimeric antigen receptor T cells (CAR T) with properties uniquely suited for use in autoimmunity and synReg T cells (synthetic regulatory T cells) to suppress pathogenic immune cells in specific organs and tissues.


Big visions require bold collaborations. We are actively exploring in-licensing and technology expansion opportunities and welcome your ideas here.


Join the front lines of a cell therapy revolution where scientists, industry veterans and health-care visionaries are creating a new class of living medicines for autoimmune disease.